|MDACC Study No:||2012-0588 (clinicaltrials.gov NCT No: NCT01656642)|
|Title:||A Phase Ib, Open-Label Study of the Safety and Pharmacology of MPDL3280A Administered in Combination with Vemurafenib in Patients with Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma|
|Principal Investigator:||Patrick Hwu|
|Treatment Agent:||MPDL3280A; Vemurafenib|
|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
of MPDL3280A that can be given in combination with vemurafenib (Zelboraf®) to
patients with locally advanced or metastatic melanoma that has a BRAF
mutation. The safety of the drug combination will also be studied.
MPDL3280A is designed to help the immune system recognize the tumors and may
help stop the their growth.
Vemurafenib is designed to block the BRAF gene mutation. This mutation causes
cancer cells to grow and multiply. By blocking this mutation, the drug may
kill the cancer cells with the mutation and/or stop the tumor from growing.